FDA approves AstraZeneca’s Tagrisso to treat mutation-positive NSCLC

This article was originally published here

AstraZeneca has secured approval from the US Food and Drug Administration (FDA) for its Tagrisso (osimertinib) 80mg once-daily tablets to treat patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC).

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply